Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M

Pixabay/Public domain

The institution is preparing for a BLA submission and an FDA gathering aboriginal this twelvemonth for tovecimig, which precocious received Orphan Drug Designation for biliary tract cancer/BTC. In a Phase 2/3 study, the tovecimig operation met its superior endpoint with a 17.1% wide effect complaint versus 5.3% for paclitaxel alone. It besides importantly improved median progression-free endurance to 4.7 months compared to 2.6 months for the power group.

Compass Therapeutics Inc. (NASDAQ:CMPX) has besides initiated cohort expansions for CTX-8371 crossed breast, lung, and lymphoma indications, with archetypal information scheduled for presumption astatine ASCO 2026. Additionally, a Phase 1 survey has commenced for CTX-10726 successful coagulated tumors, with archetypal information expected successful Q4 2026. Finally, a Phase 2 proceedings for the company’s CD137 agonist, CTX-471, is connected way to statesman successful H2 2026.

Compass Therapeutics Inc. (NASDAQ:CMPX) is simply a clinical-stage oncology-focused biopharmaceutical institution processing antibody-based therapeutics for the attraction of assorted quality diseases successful the US.

While we admit the imaginable of CMPX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.